Autologous Hematopoietic Transplantation Reduces Brain Inflammatory and Axoglial Damage Biomarkers in Multiple Sclerosis.
Laura A Cooney, Noha Lim, Kristina M Harris et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II multicenter clinical trial investigated the effects of autologous hematopoietic stem cell transplantation (AHSCT) on inflammatory and axoglial damage biomarkers in 24 patients with severe multiple sclerosis (MS). AHSCT led to significant long-lasting reductions in proinflammatory cytokines and neuroinflammatory markers in serum and cerebrospinal fluid (CSF), supporting its role in inducing disease quiescence.
Key findings
- AHSCT resulted in decreased expression of many proinflammatory cytokines and neuroinflammatory markers for several years.
- CSF levels of glial fibrillary acid protein and IL-7 increased after AHSCT.
- Changes in serum biomarkers were largely distinct from those in CSF, with few correlations.
- Neurofilament light chain (NfL) levels were the exception, showing some correlation between serum and CSF.
Why it matters
Understanding the impact of AHSCT on inflammatory biomarkers can help clinicians appreciate its potential to induce long-term immune tolerance and manage severe MS. This knowledge may guide future therapeutic strategies and biomarker monitoring.